Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 2,426 - 2,450 of 2,711

«
1
…
96
97
98
99
100
…
109
»

Prostate Cancer Updates

Prostate Cancer Updates

By: Laura Graham, MD

Prostate Cancer Updates

Prostate Cancer Updates

By: Laura Graham, MD

Master Lecture on Prostate Cancer: Targeted Therapy PSMA and More

Master Lecture on Prostate Cancer: Targeted Therapy PSMA and More

By: Marc Matrana, MD, MS, FACP

Prostate Cancer Management

Prostate Cancer Management

By: Mayer Fishman, MD, PhD

Targeting Prostate Cancer in the Metastatic Setting

Targeting Prostate Cancer in the Metastatic Setting

By: Mayer Fishman, MD, PhD

State of the Art Sequencing of Treatment in Patients with Castration Resistant Prostate Cancer

State of the Art Sequencing of Treatment in Patients with Castration Resistant Prostate Cancer

By: Michael E. Hurwitz, MD, PhD

Castration Resistant Prostate Cancer (CRPC), Non-Metastatic & Metastatic: Novel Therapeutic Advances

Castration Resistant Prostate Cancer (CRPC), Non-Metastatic & Metastatic: Novel Therapeutic Advances

By: Michael Hurwitz, MD, PhD

Castration Resistant Prostate Cancer (CRPC), Non-Metastatic & Metastatic: Novel Therapeutic Advances

Castration Resistant Prostate Cancer (CRPC), Non-Metastatic & Metastatic: Novel Therapeutic Advances

By: Michael Hurwitz, MD, PhD

Focal therapy options in Prostate Cancer

Focal therapy options in Prostate Cancer

By: Murugesan Manoharan, MD

Prostate Cancer Updates

Prostate Cancer Updates

By: Neeraj Agarwal, MD, FASCO

Prostate Cancer Updates

Prostate Cancer Updates

By: Neeraj Agarwal, MD, FASCO

State of the Art: Hormone-sensitive Prostate Cancer

State of the Art: Hormone-sensitive Prostate Cancer

By: Primo N. Lara, Jr., MD

State of the Art: Hormone-sensitive Prostate Cancer

State of the Art: Hormone-sensitive Prostate Cancer

By: Primo N. Lara, Jr., MD

PARP Inhibitors in Prostate Cancer- Who, When, and Why (not)

PARP Inhibitors in Prostate Cancer- Who, When, and Why (not)

By: Ravi A. Madan, MD

Sequencing Drugs in mCRPC

Sequencing Drugs in mCRPC

By: Sandy Srinivas - MD

Castration Resistant Prostate Cancer: What is the optimal treatment?

Castration Resistant Prostate Cancer: What is the optimal treatment?

By: Sandy Srinivas, MD

Castration Resistant Prostate Cancer: What is the optimal treatment?

Castration Resistant Prostate Cancer: What is the optimal treatment?

By: Sandy Srinivas, MD

Castration Resistant Prostate Cancer: What is the optimal approach?

Castration Resistant Prostate Cancer: What is the optimal approach?

By: Sarmad Sadeghi (USC)

Castration Resistant Prostate Cancer: What is the Optimal Treatment?

Castration Resistant Prostate Cancer: What is the Optimal Treatment?

By: Sarmad Sadeghi, MD, PhD

Castration Resistant Prostate Cancer: What is the Optimal Treatment?

Castration Resistant Prostate Cancer: What is the Optimal Treatment?

By: Sarmad Sadeghi, MD, PhD

State of the Art: Hormone-sensitive Prostate Cancer

State of the Art: Hormone-sensitive Prostate Cancer

By: Sarmad Sadeghi, MD, PhD

State of the Art: Hormone-sensitive Prostate Cancer

State of the Art: Hormone-sensitive Prostate Cancer

By: Sarmad Sadeghi, MD, PhD

Hormone Sensitive Metastatic Prostate Cancer

Hormone Sensitive Metastatic Prostate Cancer

By: Tanya B Dorff, MD

State of the Art: Hormone-sensitive Prostate Cancer

State of the Art: Hormone-sensitive Prostate Cancer

By: Tanya Dorff, MD

Prostate Cancer (no IO): Hormonal, PARP Inhibitors and Other.

Prostate Cancer (no IO): Hormonal, PARP Inhibitors and Other.

By: Ulka Vaishampayan, MD

«
1
…
96
97
98
99
100
…
109
»

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok